# US 2021/0275451 A1 · Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275451 A1
- Document ID: US20210275451A1
- Status: Published application
- Kind: A1
- Application number: 17/192,570
- Filed: 2021-03-04
- Published: 2021-09-09
- Earliest claimed: 2020-03-04
- Assignees: Somerset Therapeutics, LLC
- Applicants: Somerset Therapeutics LLC
- Inventors: Rahul Kalhapure; Prem Sagar Akasapu; Veerappan Subramanian; Ilango Subramanian
- Web page: https://patentgrep.com/patent/US20210275451A1

## CPC

- A61K 9/10: Dispersions; Emulsions
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a process for preparation of an insoluble corticosteroid and a soluble corticosteroid composition by moist heat sterilization and homogenization. In particular, the invention relates to a process for the preparation of a sterilized suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises sterilizing a slurry of the betamethasone acetate by moist heat sterilization or autoclaving in about 30% to about 70% of water to a temperature of about 115° C. to about 128° C. for about 15 minutes to about 60 minutes under nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

## Claims

### Claim 1

A process for preparing a sterile injectable suspension of an insoluble corticosteroid and a soluble corticosteroid, wherein the process comprises:
moist heat sterilizing a slurry of the insoluble corticosteroid in water to form a sterile slurry;
aseptic addition of an aqueous solution comprising betamethasone sodium phosphate and one or more formulation excipients to the sterile slurry; and
homogenization of the aqueous solution and the sterile slurry to form the sterile injectable suspension.

### Claim 2 (depends on 1)

The process for preparation of claim 1, wherein the insoluble corticosteroid is betamethasone acetate.

### Claim 3 (depends on 1)

The process for preparation of claim 1, wherein the soluble corticosteroid is betamethasone sodium phosphate.

### Claim 4 (depends on 1)

The process for preparation of claim 1, wherein the weight ratio of the insoluble corticosteroid to the soluble corticosteroid has a range of about 1:1.39.

### Claim 5 (depends on 1)

The process for preparation of claim 1, wherein the process comprises dispersing betamethasone acetate into water and sterilizing to a temperature of about 115° C. to about 128° C. for about 15 minutes to about 60 minutes under a nitrogen atmosphere.

### Claim 6 (depends on 1)

The process for preparation of claim 1, wherein the concentration of insoluble corticosteroid in the slurry varies from about 0.1% to about 2%.

### Claim 7 (depends on 2)

The process for preparation of claim 2, wherein the betamethasone acetate in the suspension has a particle size range of from about 0.1 μm to about 30 μm.

### Claim 8 (depends on 1)

The process for preparation of claim 1, wherein the suspension is not sterilized in a sterilization process that includes a step of a terminal sterilization.

### Claim 9 (depends on 1)

The process for preparation of claim 1, wherein the suspension comprises about 0.3% betamethasone acetate, about 0.3% betamethasone sodium phosphate, about 0.9% dibasic sodium phosphate dihydrate, about 0.4% monobasic sodium phosphate dihydrate, about 0.01% edetate disodium, about 0.02% benzalkonium chloride and water.

### Claim 10 (depends on 1)

The process for preparation of claim 1, wherein the suspension pH is in the range of about 6.8 to about 7.2.

### Claim 11 (depends on 10)

The process for preparation of claim 10, wherein the suspension is suitable for intramuscular and intra-articular use.

### Claim 12 (depends on 1)

The process for preparation of claim 1, wherein the slurry comprises about 30% to about 70% of the water in the sterile injectable suspension.

### Claim 13

A process for preparing a sterile injectable suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises:
moist heat sterilizing a slurry of the betamethasone acetate in water to form a sterile slurry;
aseptic addition of an aqueous solution comprising betamethasone sodium phosphate and one or more formulation excipients to the sterile slurry; and
homogenization of the aqueous solution and the sterile slurry to form the sterile injectable suspension.

### Claim 14 (depends on 13)

The process for preparation of claim 13, wherein the weight ratio of betamethasone acetate and betamethasone sodium phosphate has a range of about 1:1.39.

### Claim 15 (depends on 13)

The process for preparation of claim 13, wherein the betamethasone acetate particles in the suspension have a D90 value of about 10 μm to about 20 μm.

### Claim 16 (depends on 13)

The process for preparation of claim 13, wherein the suspension provides entire drug release in about 6 hours.

### Claim 17 (depends on 13)

The process for preparation of claim 13, wherein the slurry comprises about 30% to about 70% of water of the sterile injectable suspension.

### Claim 18 (depends on 13)

The process for preparation of claim 13, wherein the concentration of the betamethasone acetate in the slurry comprises from about 0.1% to about 2%.
